Ladies and gentlemen, good day and welcome to the Shaily Engineering Plastics Limited Q2 FY 2024 earnings conference call. This conference call may contain forward-looking statements about the company, which are based on beliefs, opinions and expectations of the company as on the date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict.
As a reminder, all participant lines will be in the listen only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Amit Sanghvi, Managing Director, Shaily Engineering Plastics Limited. Thank you and over to you, sir.
Thank you very much. Good evening and a very warm welcome to all the participants to the post-results earnings call of Shaily Engineering Plastics Limited. I have with me Sanjay Shah, our Chief Strategy Officer, and now also our Chief Financial Officer, and SGA, our investor relations advisors. I hope you've had a look at our investor presentation that is uploaded on our website and the stock exchange. Let me give some highlights on the operational and the business performance for the quarter.
Despite a challenging global environment, we delivered a top line of INR 158 crore, and we've improved our gross margins and EBITDA margins, which stand at 41.1% and 17.16% respectively. You're all aware that we have spent significant time in developing drug delivery platforms based on our own IP, and have also made significant capital investments in creating new facilities for scale-up. These efforts are finally yielding results, and we're now seeing the start of commercialization of some of our platforms.
I'm happy to announce that we've received our first commercial, which is post-EB batches purchase orders from a few customers for some of our platforms. I would only reiterate that in this sector, our business scope is very extensive, and we are committed to continuous growth in the coming months and years. In addition to commercialization of our own products, we have also been awarded a new applicator project, for which we will start supplies in July 2024, where the total value of the additional business is INR 35 crore per annum.
On the home furnishings front, we have been awarded business for new products whose total value stands at INR 50 crore per annum, for which supplies will start in quarter two of FY 2025. We are strengthening our relationship with customers. We are also working with the home furnishings major on scale-up of our steel furnishings business and have received business confirmations for additional volumes that will see improved utilization not only in the current year, but also in the next.
In the automotive and engineering segment, we have added three new products, and the total business value stands at INR 3.5 crore-INR 5 crore per annum. We're delighted to announce that we have been awarded a new order of supply of six components in the engineering segment by one of our oldest customers, ASCO. That is all from my side. I shall now hand over the call to Sanjay Shah to give you the operating and financial highlights. Thank you very much.
Thank you, Amit. Good evening, everyone. I shall share with you the highlights of our operational and financial performance for Q2 and H1 FY 2024, following which we will be happy to respond to your queries. During the quarter, we processed 5,673 tons of polymers as against 5,145 tons in Q1 FY 2023. For the half year ended, we processed 11,495 tons of polymers as against 11,905 tons in H1 FY 2023. Machine utilization rate was around 40% in Q2 FY 2024 and 41.5% in H1 FY 2024. Exports during H1 FY 2024 stood at 74.5% of total revenue. I shall brief you on standalone results highlights for Q2 FY 2024.
Revenues stood at INR 155.7 crore during Q2 FY 2024 as compared to INR 160 crore during Q2 FY 2023. EBITDA stood at INR 25.5 crore during Q2 FY 2024 as compared to INR 25.1 crore during Q2 FY 2023. EBITDA margin stood at 16.4% for Q2 FY 2024, an increase of 70 basis points over Q2 last year. PAT stood at INR 9.9 crore during Q2 FY 2024 as compared to INR 9.4 crore during Q2 FY 2023. PAT margin stood at 6.3%, an increase of 40 basis points over Q2 last year. Cash PAT for Q2 FY 2024 was reported as INR 17.9 crore as compared to INR 17.1 crore during Q2 FY 2023. Coming to H1 FY 2024 highlights.
Revenues stood at INR 308.5 crore in H1 FY 2024 as compared to INR 332 crore during H1 FY 2023. EBITDA stood at INR 49.2 crore in H1 FY 2024 as compared to INR 46.8 crore during H1 FY 2023. A growth of 5%. EBITDA margin stood at 16%, an increase of 190 basis points over H1 last year. PAT stood at INR 18.5 crore in H1 FY 2024 as compared to INR 16.8 crore during H1 FY 2023, a growth of 10%. PAT margins stood at 6% and increase of 90 basis points over H1 last year.
Cash PAT for H1 FY 2024 was reported at INR 34.7 crore as compared to INR 32.2 crore during H1 FY 2023. Our ROCE and ROE stood at 14% and 9.3% respectively as on September 30th, 2023. This growth in business is being achieved with disciplined use of capital. Our debt to equity stands at 0.5x, and our long-term debt to equity stands at 0.15x. Now I shall brief you on the consolidated result highlights. Revenues stood at INR 157.6 crore during Q2 FY 2024 as compared to INR 161.3 crore during Q2 FY 2023. EBITDA stood at INR 26.6 crore during Q2 FY 2024 as compared to INR 25.9 crore during Q2 FY 2023.
EBITDA margins stood at 16.9% for Q2 FY 2024, an increase of 80 basis points over Q2 last year. PAT stood at INR 10.8 crore during Q2 FY 2024 as compared to INR 10.1 crore during Q2 FY 2023. PAT margins stood at 6.9%, an increase of 70 basis points over Q2 last year. Cash PAT for Q2 FY 2024 was reported at INR 18.9 crore as compared to INR 17.7 crore during Q2 FY 2023. Now coming to H1 FY 2024 consolidated highlights. Revenues stood at INR 314.9 crore in H1 FY 2024 as compared to INR 336.3 crore during H1 FY 2023.
EBITDA stood at INR 54.2 crore in H1 FY 2024 as compared to INR 50.2 crore during H1 FY 2023, a growth of 8%. EBITDA margins stood at 17.2%, an increase of 230 basis points over H1 last year. PAT stood at INR 23.4 crore in H1 FY 2024 as compared to INR 19.6 crore during H1 FY 2023, a growth of 20%. PAT margins stood at 7.4%, an increase of 160 basis points over H1 last year. Cash PAT for H1 FY 2024 was reported at INR 39.7 crore as compared to INR 31.1 crore during H1 FY 2023. This is all from our side. Now we can open the floor for Q&A. Thank you.
Thank you. Ladies and gentlemen, we will now begin with the question- and- answer session. Anyone wishing to ask a question may please press star and one on your touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. Participants, if you wish to ask a question, you may please press star and one. The first question is from the line of Aman Vij from Astute Investment Management. Please go ahead.
Good evening, sir. It was good to hear about the possible commercialization starting for our device business. Just on that part first, we were waiting for, I think, the U.S. FDA clearance from one of our clients. So does everything that is now completed and this will result in commercialization, or this is some other products or projects we are talking about?
This is another pen, Aman. Again it's not that FDA clearance has come in. They are anticipating FDA clearance to come in, but are preparing for commercial orders.
This is apart from that. This is-
Yes.
...new commercialization right there.
Yeah.
Sure. My next question is, basically in the annual report we have talked-
Aman, we are losing your voice.
Sorry to interrupt, Aman. Can you speak a bit louder? We are not able to hear you.
Yeah. Is it better now?
Yes.
Just slightly better. Can you switch to handset mode?
Hello?
Yes, sir. Please proceed.
Yeah. My next question was, we had talked about our target to sell around 15 million pens by the end of this year. Are we on track to do that? Will the bulk of the sales happen in H2 or already in H1 we have had a majority of that target hit?
No, we have not had majority of the target in H1. Quarter three and quarter four will see bulk of the sales, but we will likely not get to 15 million. There's going to be a shortfall. Not a very significant one, but there will be a shortfall.
Sure. Any kind of targets we have for the next year?
We'll assess the situation on sales in quarter three and quarter four, and then give an update during the beginning of next year.
Sure.
Certainly growth, but we don't know how much at this point.
Sure, sir. On the own IP pens, is it safe to assume that majority of this is currently insulin-linked only rather than the new molecules?
Can you repeat that, Aman? We lost you again.
Yeah. Sure, sir. I was saying in terms of own IP sales, own IP pen sales. Is it right to assume that majority of this is insulin-linked rather than we are entering a lot of new areas. Is it safe to assume that as of today?
No. On our own IP products, it's not insulin-linked. It's more GLP-1s than parathyroid hormones.
Sure. That helps. Sir, we had recently, I believe, participated in CPHI conference. If you can talk about how was the response, given how we have a very extensive range of platforms available to offer to our customers.
The plan was to give a full CPHI update on the next call because the CPHI happens in October. Just to put it very shortly, very briefly, we had a fantastic conference. I don't think I had an idle minute at the conference from day one till the last day. Very positive response, not only from generics, but also from some innovator companies.
Sure. As of now, how many international customers do we have for distribution?
We have two international customers at the moment.
Okay. Given the response, do you see this number going substantially in the next two, three years?
I don't know. Yes. From a baseline of two, it will grow substantially.
Sure, sir. Just final question from my side. I'll get back in the queue. The new orders which you have talked about which will get executed mostly next year, these are in addition to the orders we had in Q1?
Yes.
These are totally new orders?
Yes. The home furnishings order or the automotive engineering order or even the order on the healthcare space, all of these are new orders which have happened in the current quarter.
The remaining, the Q1 which you had talked about, some of the orders is expected to execute in, I believe Q4 onwards. That is still on track?
That is still on track.
Sure, sir. I'll get back in queue. I have more questions. Thank you.
Thank you.
Thank you. A reminder to the participants, anyone wishing to ask a question, may please press star and one. The next question is on the line of Priyank Parekh from Abakkus Asset Manager. Please go ahead.
Yeah. Thanks for the opportunity. Sir, wanted to understand the sales mix that we have in current quarter vis-a-vis the March 2023 quarter, wherein we have seen substantial high EBITDA margin compared to the last two quarters. Just wanted to understand how sales mix has shifted.
Priyank, in the March quarter, I think we had also mentioned this on the call. While we do not give individual numbers, but we had said we had fairly large revenue coming in from the healthcare or the device space where we supplied insulin batches to some customers and there were three or four shipments which were made. All of them were bunched in January. That's the reason you saw that bump up happening. What we are also seeing is when you look at last year to this year, we are seeing a slow improvement in the EBITDA margin, which is what we expect to continue going forward.
Okay. As you mentioned that bulk of the sales of-
Hello?
Hello. We lost him.
Give me a minute. Yes, sir. Sir, the line for the current participant has dropped off. We'll move on to the next question. That is from the line of Nirali Gopani from Unique PMS. Please go ahead.
Hi, sir. Thank you for the opportunity. Sanjay, my first question is to you on the gross margin side. If I see the gross margin for this quarter compared to the last quarter-on-quarter, there is a good decline of 3%. Sir, can you share your thoughts on that?
Nirali, when you look at from quarter one to quarter two, you will also see that when you look at standalone and consolidated, you will see revenues from our U.K. subsidiary have been a little lower as compared to quarter one.
Right.
There have been some lesser revenues on the pharma front, that's the reason we are seeing a reduction in the gross margin. It's more of a mix thing than anything else.
Okay, perfect. Amit, you have been sounding very positive on the next two quarters of this financial year. If you can highlight, how do you see the growth coming in for the next two quarters? Can we see a top line of somewhere about INR 175 crore-INR 200 crore coming in the next two quarters?
I think I'm very confident of bottom-line growth. Top-line growth, I'm not confident of INR 200 crore in the next two quarters. Top-line growth will be there, but it won't be to that tune. I feel bottom-line growth will be more substantial in the next two quarters.
Largely backed by a higher margin because of the healthcare segment.
That's right.
Also, if I see the last two quarters, we have roughly announced new orders worth of INR 190 crore-INR 200 crore. When we look at FY 2025, in addition to this INR 200 crore, the base business should also grow substantially, and hence FY 2025 should see exponential growth on revenue and margins. Is this understanding correct?
We will see growth. I don't want to put in an adjective there in terms of exponential or not. Yeah, we will see growth on the top line as well as at the margin level. How will we see your? Current situation is that there's a lot of uncertainty in demand. While we've gotten new business, we don't know what will happen to the demand for preexisting business, especially in the non-healthcare side of the business. Like Sanjay said, there'll certainly be growth, both top and bottom line. Whether it will be INR 200 crore, whether there'll be something that gets eaten up in the current business, it's a little too early to tell at this point. We will provide that update likely in quarter four.
Oh, perfect. That's it from my side. Thank you.
Thank you, Nirali.
Thank you. The next question is from the line of Priyank Parekh from Abakkus Asset Manager LLP. Please go ahead.
Yeah, thank you. Just wanted to understand the INR 49 crore of CapEx that we have done on the first half. For what this CapEx is done, and secondly, how is the CapEx outlook for the next half of this year?
Priyank, a large part of this CapEx is the continuing CapEx which we did in terms of expanding our pharma facility or device manufacturing facility. CapEx is for that reason. We have completed a large part of this CapEx during H1 of FY 2024. There is some spill-over which will happen in Q3, which will continue. I think from a major CapEx cycle, we would be completely over by Q3 of FY 2024.
Okay, got it. For our toys business, are we having any update compared to the previous quarter where we were not seeing substantial business in toy segment?
I think we will still continue with the same view as we talked about in quarter one.
Okay.
We're not actively pursuing toys business at this point. We'll participate where there is value add, but otherwise we're not actively pursuing.
Okay. Over the last three, four years, there has been substantial import substitution has been happening in India, especially in toys. Are we seeing any opportunity from that perspective?
Not quite for the-
Priyank, we've not seen a lot of opportunities there, especially because I do agree with you that there's some localization happening, but none of the local guys have volumes to basically look at making investments in tooling and everything.
Okay. My last question also on our hunt for the CEO. Are we having any development on that side?
It is very unfortunate. We had finalized a CEO and the person was to join in the next two weeks, but he has pulled out.
Oh, okay.
We're going to have to start the search again.
Okay. Yeah. Thank you. That's it from my side.
Thank you, Priyank.
Yeah.
Thank you. The next question is on the line of Harshil Shethia from AUM Fund Advisors LLP. Please go ahead.
Hi, sir. Can you comment on the carbon steel business? What kind of utilizations are we at? In the last quarter you had mentioned about ramp-up. What kind of pipeline is there in the same business?
Harshil, we have seen improvement at the utilization level in that plant. We continue to work with the customers to basically see how we can improve utilization level going forward. If we were to compare Q2 of last year to Q2 of this year, we have seen substantial improvement in the utilization levels as well as on the top line. Even if you were to compare Q1- Q2, we have seen improvement.
Okay. Because in the previous quarter, we had also mentioned that that would lead to a better margin improvement. Due to operating leverage kicking in. Do we see any kind of margin improvement in the same? Or if you can guide, say, by 100 basis points or 150 basis points or whatever.
Sure. Harshil, if you were to look at Q1 and Q2 of last year and then compare it with Q1 and Q2 of this year, you have seen margin improvements happening in Q1, Q2 or even H1 over last year. A large part of that margin increase is coming in from the healthcare, but part of it is also coming in where we have been able to plug the leakages around carbon steel with improved utilization levels and everything. That's a combination of these factors.
Are we at break-even in the carbon steel business?
We will not be able to talk about individual businesses, Harshil.
Okay.
Thank you. The next question is on the line of Miraj from Arihant Capital. Please go ahead.
Yeah. Thank you for the opportunity and congratulations, Sanjay, sir, on the appointment as CFO. Just had a couple of questions. Was looking at the volumes for the quarter. Could you please highlight which segments grew slower than expected, and which segments grew as expectations? That would be my first question.
Home furnishings grew as what we expected. Home furnishings and FMCG grew as what we expected. Some of our shipments on our healthcare have moved from quarter two to quarter three. I think when we look at it from the whole year perspective, I don't think we will basically have an issue in terms of the shipments, because these are development projects where it does take some time.
Okay, got it. Sir, in the presentation on the sixth slide, it is written that we have got new order for supply of six components to ASCO, to the oncology society. If you could please just highlight. I still did not understand what exactly this order was for.
ASCO is an existing customer, basically manufacturing, engineering components and everything. We have been supplying to ASCO for over 20 years now, 18-20 years. This is a new order book which we have got from them. That is what we have talked about.
Okay. Could we quantify how much is the order value worth here, or that is not possible?
The volumes will differ year-on-year, that is the reason we have not quantified the volume.
Sir, just final question before I get back in the queue. On the same page, it is written that we've decided for the split of shares, I found no other release on exchanges. That is approved by the board or that is still going to happen in the next meeting?
Miraj, that has been approved by the Board. That has also been approved by the shareholders. This was done post the last quarter board meeting. We had a separate meeting for that. It has been approved by the Board. It has been also approved by the shareholders in the AGM. We are going through the normal process. From an INR 10 share, we are taking it to INR 2. It will be five shares for every one share held. The whole process should get completed probably by end of November.
Perfect. Thank you so much. I'll get back in the queue. Thank you.
Thank you.
Thank you. A reminder to the participants, anyone wishing to ask a question, may please press star and one. The next question is from the line of Rajvi Shah from Bright Securities. Please go ahead.
Thank you for the opportunity. I had few questions. The first one is, sir, can you elaborate more on the order that you have received in the last quarter related to new applicator product in the pharma space?
What kind of elaboration are you looking for, Rajvi?
Like on the order perspective.
Rajvi, I think the order value has been given. What we have also said is we will be looking at commercializing this in Q2 of FY 2025. Rest of it, we would be bound by NDA in terms of what exact application and everything is. This is going to be a recurring order. It will be a yearly order which will be recurring year-on-year.
Okay. The next question I had is, sir, on home furnishing segment. We have received new supply for which segment? Also, any development on addition of customer in home furnishing? Which geography and what type of customers are we targeting for this segment?
We continuously work with our existing customer on the home furnishing segment. This order is from our existing customer. We supply to this customer all across the group wherever they have stores. Supplies are predominantly to Europe and U.S., we also supply to China, Asia, Middle East, and other places wherever they have stores.
Okay, that was helpful. Thank you.
Thank you very much.
Thank you. The next question is from the line of Richa Agarwal from Equitymaster. Please go ahead.
Thank you for the call, its Richa . My question was-
Sorry to interrupt, ma'am. We are unable to hear you clearly.
Sorry-
No, ma'am.
We can join back in-
Thank you. A reminder to the participants, anyone wishing to ask a question may please press star and one. The next question is from the line of Nirali Gopani from Unique PMS. Please go ahead.
Thanks for the opportunity again. Sir, in this quarter, we have seen a good jump in other income. Any particular reason, and what does it include?
No, this is a normal thing, so there's nothing one-off, which is there.
Nothing related to the operations of the business, right? Ideally, if I eliminate other income and see the EBITDA.
Yeah. Most of our other income would also be related to our business only.
Okay. If I eliminate the other income and see the EBITDA margin, there is a decline sequentially because of, obviously, the gross margin. Just wanted to understand when you say that you see a significant jump in the EBITDA margin in the coming quarter and say next year, so from what level should we see this growth?
Just to answer your first question. The other income basically includes FX gain, this is related to the business.
Okay.
Can you repeat your second question, Nirali?
If I eliminate other income, I was just seeing an EBITDA margin of 15% for the quarter. I just wanted to understand when we say a growth in EBITDA margin in the next two quarters or over FY 2025, from what level should we see this growth, from current growth of 17%, which is mentioned in the presentation?
Similarly, I think looking at Shaily's margin on a quarter-on-quarter basis would not be correct. What I would again reiterate is when we look at margins, we look at the full year's margins, which we achieved for FY 2023. Based on that, we are looking at growth in FY 2024 and FY 2025 going forward.
Perfect. Next year. Thank you.
Yeah.
Thank you. The next question is from the line of Aman Vij from Astute Investment Management. Please go ahead.
Sir, on the healthcare side, what kind of growth are we expecting in the second half?
Can you elaborate the question a little bit?
At the start of, I think, last quarter, you had talked about you are targeting very high growth for the full year.
Yeah.
Are we on track of that? Is it lower than our expectation? Is it much higher than our expectation, if you can talk about that part.
We are on track to achieve that growth. Again, like I said, the 15 million pens, it's going to be a little bit less than that. Whatever drop that entails will be the only drop. Otherwise, we are on track to achieve that.
That 50%-60% kind of growth on healthcare side still stands.
Yes.
Sure, sir. Sir, a lot of the Indian generic players are facing some of the other issue related to U.S. FDA audits recently. Do you think this can have an impact on our plans as well?
Yeah. I mean, they can certainly have an impact on our plans. All the ones we're looking at commercializing or have started restart shipment of commercial orders, we have not seen those customers face an issue with the FDA. There could be a potential longer-term impact, but nothing in the next 24 months that I can see today.
Sure, sir. In terms of number of projects addition, and by projects I mean, say, one customer, one pen, one platform. What kind of additions do you think will happen for this year and next year?
I mean, we're having active discussions with probably a dozen or more customers on various molecules and devices. I would assume that at least 60% we should be able to convert.
Aman, just to add to what Amit said is, I think every quarter we intimate you guys in terms of what is happening. That's what we would do.
Just final thing on this part, in the presentations, in terms of the platforms we have shown, I could not see the Neo platform. You have shown the other five. Neither I could see the Mira platform, which is available on the website. Any reasons for not including those?
Neo, we are not showing it for some specific reasons.
The Neo platform will be updated on our presentations. We have already created our new healthcare presentation. You will probably see it in the next quarter.
Sure. These are the questions. Thank you.
Thank you. The next question is from the line of Miraj from Arihant Capital. Please go ahead.
Thank you for the follow-up opportunity. Sir, on the healthcare side, I wanted to understand the kind of prospects that differ when we sign with an innovator and a generic player. If you could just throw some light what kind of opportunities would differ and if we are in talks with any innovator right now in advanced stages.
We are in talks with an innovator on a novel molecule. I would probably not say that it's a very advanced stage. It's not an initial stage conversation, I think, but somewhere in between. We're going through the evaluation process of our devices that are suitable for their molecule and primary container. Once that is complete, we will undertake the agreement discussions.
That will be a new one for us where we have a new chemical entity that we onboard, hopefully onboard. With generics, we understand the markets a lot better because we know what is coming to an expiry, what is going to have an NCE-1 filing deadline. Our development is largely based on that. Some of our development also happens for innovators, largely all the platforms that we have been able to commercialize or get to design verification are based on the deadlines that we see with the generic industry.
Right. The innovator, if we sign any innovator, I'm just not putting up the question that we are going to, the opportunities will be significantly different from what we have with generic players, or would it be in the same range, I mean, in terms of volumes that we may do? Just wanted to understand that.
See, with a generic player, you know the volume because you know what the innovator is doing and how much of a market share generics can take up. With an innovator, with a new chemical entity, you're not going to know what the volumes will be. They're essentially projections, right? There is certainly a very high upside if the drug does well, there's also a downside if the drug doesn't do well. With the generic business, there is more clarity in terms of what your future will look like.
Got it. My final question, sir, on the FMCG side that we've mentioned there's a new packaging development. Is it a product-based development or is it some client-based development? If you could just explain what exactly is the development there?
It is a client-based development.
Okay. Yeah. Thank you. You'll be sharing more details in the next quarter, right? Once it is in progress.
Yeah. This order has already been confirmed. We're doing the development now. We would start supplying between four to six months.
Okay, perfect. All the best, sir. Thank you.
Thank you.
Thank you. The next question is from the line of Richa from Equitymaster. Please go ahead.
Thank you for the opportunity. Sir, my question was related to the CapEx that you were suggesting, a part of it will be more or less done by third quarter. Just wanted to understand, for whatever growth in pharma we are expecting 2x-3x , will this CapEx be enough, the gross block could be enough to cater to that kind of growth? Currently the turnover is 0.9x. What kind of turnover could you expect based on the product mix that you envisage two to three years from now on the current gross block?
Richa, what we have said is, a large part of our pharma CapEx is done. We have created space for a total of additional 36 molding machines, out of which 12 molding machines have been put in. We will need to add another 12 + 12, 24 machines, but they will be added gradually as the ramp-up happens and once the utilization levels within the existing pharma facility improve.
What kind of utilization turnover we are looking at once these capacities get settled and optimally utilized?
Again, I think giving individual numbers would basically be difficult.
No.
Sorry, I lost you. I can't hear you.
Overall, currently your gross block or-
Yeah. That's what I was coming to. On an overall gross block, what we have said is somewhere between 2.25%- 2.5% of our fixed asset investment is the turnover which we would be able to reach.
Okay. Thank you, Sanjay.
Thank you.
Thank you. The next question is from the line of Bhavin Rupani from Investec. Please go ahead.
Yeah. Hi, sir. Thanks for the opportunity. Sir, just wanted to understand how should one look at the margins and the CapEx requirement for the new orders that we have announced in Q1 and Q2?
The new orders which we announced in Q1 and Q2, we would be basically utilizing our existing infrastructure, which we have, and we are basically adding in our healthcare facility. That will take care of the orders.
You are saying that no additional CapEx is required?
There'll be some marginal CapEx, but nothing substantial.
Okay. Sir, how should one look at the margins as compared to the existing company level margins?
Again, every business will have different margins, so it'll be difficult for me to quote on. As said, on an overall basis, we expect going forward margins to improve as the top line improves.
All right. Sir, just one clarification. Is it correct that we're looking at margin expansion in FY 2024 versus FY 2023? Is my understanding correct?
If you look at H1 numbers and compare it with H1 numbers last year, you have seen margin expansion at the EBITDA level and at the PAT level. We hope we continue that for the balance part of the year.
All right. Thank you so much for the answers, sir. Thank you.
Thank you.
Thank you. A reminder to the participants, anyone wishing to ask a question may please press star and one. If there are no further questions, I now hand the conference over to management for the closing comments.
Thank you everyone for joining the call. We hope that we've been able to answer your questions adequately. For any further information, I request you to get in touch with SGA, our investor relation advisors. Thank you, have a great evening.
Thank you, members of the management team. Ladies and gentlemen, on behalf of Shaily Engineering Plastics Limited, that concludes this conference call. We thank you for joining us. You may now disconnect your lines. Thank you.